AI Podcast Interviews Articles and Reports

This interview analysis is sponsored by Aquant was written, edited and published in alignment with our Emerj sponsored content guidelines. Learn more about our thought leadership and content creation services on our Emerj Media Services page.

Due to technological advancements, automakers are uniquely positioned to benefit from an industry-wide transformation. Technology now allows a direct connection between car manufacturers and the customers who purchase those cars. Such a relationship has never before been possible in the history of the automotive industry.

With the rapid proliferation of generative AI tools, there is growing anticipation of their potential to bring about notable changes in the financial and business sectors. Examples such as the creation of "the new Bing" – a combination of Microsoft's Bing search engine and ChatGPT, which can generate more reliable and comprehensive answers – and other generative AI tools used to create videos for product design, have all contributed to the expectations within various sectors.

Lily is a pharmaceutical giant with a legacy dating back to its founding in 1876 by Colonel Eli Lilly. The company engages more than 9600 employees in research and development, with clinical research conducted in more than 55 countries. As of 2022, the company clocked a revenue of $28,541.4 million and made a net income of $6,244.8 million. 

Edge AI, also known as edge intelligence, is a term that refers to the convergence of two dynamic technological trends: edge computing and Artificial Intelligence. In today's tech landscape, the proliferation of mobile devices and advancements in communication technologies have fueled the rise of edge computing, which focuses on processing data at the network edge. 

AI is driving change across many industries, including logistics and manufacturing. Companies need to strike the right balance between automation and human intervention. This interaction represents a specific area of study known as human-automation interaction. 

AI has profound implications for drug discovery, ushering in a new era of innovation and efficiency. Recent milestones - such as the first AI-designed drug molecule to enter human clinical trials and the prediction of protein structures for millions of proteins - showcase the transformative power of AI in this domain.

Navigating AI's challenges in transforming critical business operations applications are two pivotal aspects driving what is becoming a right of passage for nearly every industry in the evolution of modern enterprises. As organizations strive to harness the power of AI, they encounter intricate challenges, from data extraction to the complex task of molding AI into a tool that enhances various business functions.